These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 342255)
1. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264--137) in advanced human cancers. Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Xuong N; Le Pecq JB; Paoletti C Eur J Cancer (1965); 1978 Feb; 14(2):205-6. PubMed ID: 342255 [No Abstract] [Full Text] [Related]
2. Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer. Juret P; Le Talaer Y; Couette JE; Delozier T Eur J Cancer (1965); 1980; Suppl 1():277-9. PubMed ID: 7032940 [No Abstract] [Full Text] [Related]
3. [Hydroxy 9-methyl 2-ellipticinium acetate (NSC 264-137). Toxicologic study and therapeutic effect in 100 cancers (author's transl)]. Juret P; Tanguy A; Girard A; Le Talaer JY; Abbatucci JS; Dat-Yuong ; Le Pecq JB; Paoletti C Nouv Presse Med; 1979 Apr; 8(18):1495-8. PubMed ID: 471724 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137). Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658 [TBL] [Abstract][Full Text] [Related]
5. [Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)]. Juret P; Couette JE; Delozier T; Le Talaer JY Bull Cancer; 1981; 68(3):224-31. PubMed ID: 7039729 [TBL] [Abstract][Full Text] [Related]
6. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia]. Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group. Anderson G; Clavel M; Smyth J; Giaccone G; Gracia M; Planting AS; Dalesio O; Kirkpatrick A; McVie G Eur J Cancer Clin Oncol; 1989 May; 25(5):909-10. PubMed ID: 2737223 [No Abstract] [Full Text] [Related]
8. 2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study. Tura S; Mandelli F; Mazza P; Cimino G; Anselmo AP; Amadori S Chemioterapia; 1984 Apr; 3(2):79-82. PubMed ID: 6532540 [TBL] [Abstract][Full Text] [Related]
9. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience. Juret P; Heron JF; Couette JE; Delozier T; Le Talaer JY Cancer Treat Rep; 1982 Nov; 66(11):1909-16. PubMed ID: 7139636 [TBL] [Abstract][Full Text] [Related]
10. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)]. Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136 [TBL] [Abstract][Full Text] [Related]
11. [2 N methyl 9 hydroxy-ellipticine in treatment of metastatic breast cancers (author's transl)]. Rouëssé J; Huertas D; Sancho-Garnier H; Le Chevalier T; Amiel JL; Brulé G; Tursz T; Mondésir JM Bull Cancer; 1981; 68(5):437-41. PubMed ID: 7037078 [TBL] [Abstract][Full Text] [Related]
12. Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium). Einzig AI; Gralla RJ; Leyland-Jones BR; Kelsen DP; Cibas I; Lewis E; Greenberg E Cancer Invest; 1985; 3(3):235-41. PubMed ID: 4005651 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of metastatic renal cancer in adults with elliptinium acetate]. Amiel JL; Rouessé J; Droz JP; Caille P; Travagli JP; Théodore C; Le Chevalier T; Ducret JP; Bidart M; Garnier HS Presse Med; 1984 Jun; 13(25):1555-7. PubMed ID: 6234539 [TBL] [Abstract][Full Text] [Related]
14. [Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)]. Rougier P; Ychou M; Droz JP Bull Cancer; 1988; 75(10):979-81. PubMed ID: 2851337 [TBL] [Abstract][Full Text] [Related]
16. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl. Auclair C; Pierre A; Voisin E; Pepin O; Cros S; Colas C; Saucier JM; Verschuere B; Gros P; Paoletti C Cancer Res; 1987 Dec; 47(23):6254-61. PubMed ID: 3677074 [TBL] [Abstract][Full Text] [Related]
17. [Randomized trial of elliptinium acetate and tamoxifen in the treatment of inoperable hepatocellular carcinoma]. Jouanolle H; Delamaire D; Deugnier Y; Lhéry D; Simon M; Brissot P; Bourel M Gastroenterol Clin Biol; 1986 Feb; 10(2):185-7. PubMed ID: 3009255 [No Abstract] [Full Text] [Related]
18. Dynamics of drug-DNA interactions: a comparative temperature jump study of ellipticinium and 9-hydroxy ellipticinium. Schwaller MA; Aubard J; Dodin G J Biomol Struct Dyn; 1988 Dec; 6(3):443-58. PubMed ID: 3271531 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737 [TBL] [Abstract][Full Text] [Related]
20. Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro. Dugue B; Paoletti C; Meunier B Biochem Biophys Res Commun; 1984 Oct; 124(2):416-22. PubMed ID: 6388575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]